Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate Efficacy and Safety of CLR-07-23 (Heparan Sulfate 120 mg Prolonged-release Tablets) in the Treatment of Primary Chronic Venous Disease

NCT07684833 is registered in ClinicalTrials.gov with Barbara Maglione as lead sponsor.

NCT NCT07684833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate Efficacy and Safety of CLR-07-23 (Heparan Sulfate 120 mg Prolonged-release Tablets) in the Treatment of Primary Chronic Venous Disease
Lead sponsor
Barbara Maglione
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
May 31, 2027
Enrollment
174 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic venous disease, vein disease, venous insufficiency of leg